RU2019104888A - DIAGNOSTICS, TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH THE NEUROTENSIN RECEPTOR - Google Patents
DIAGNOSTICS, TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH THE NEUROTENSIN RECEPTOR Download PDFInfo
- Publication number
- RU2019104888A RU2019104888A RU2019104888A RU2019104888A RU2019104888A RU 2019104888 A RU2019104888 A RU 2019104888A RU 2019104888 A RU2019104888 A RU 2019104888A RU 2019104888 A RU2019104888 A RU 2019104888A RU 2019104888 A RU2019104888 A RU 2019104888A
- Authority
- RU
- Russia
- Prior art keywords
- alkylene
- acid
- compound
- alkyl
- heteroarylene
- Prior art date
Links
- 102000017922 Neurotensin receptor Human genes 0.000 title claims 2
- 108060003370 Neurotensin receptor Proteins 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- -1 carboxyethyl Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 125000005549 heteroarylene group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 239000002738 chelating agent Substances 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 2
- HBBSDZXXUIHKJE-UHFFFAOYSA-N 6-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=CC=C(C(O)=O)C=N1 HBBSDZXXUIHKJE-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- FHQWIXXRHHMBQL-UHFFFAOYSA-N 2-[1,3,10-tris(carboxymethyl)-1,3,6,10-tetrazacyclododec-6-yl]acetic acid Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CN(CC(O)=O)CC1 FHQWIXXRHHMBQL-UHFFFAOYSA-N 0.000 claims 1
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 claims 1
- WTHDJYYROCOPPR-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclotridec-1-yl]acetic acid Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WTHDJYYROCOPPR-UHFFFAOYSA-N 0.000 claims 1
- PCRXLSFRVKMHEJ-UHFFFAOYSA-N 2-[4-(carboxymethyl)cyclononyl]acetic acid Chemical compound C1(CCC(CCCCC1)CC(=O)O)CC(=O)O PCRXLSFRVKMHEJ-UHFFFAOYSA-N 0.000 claims 1
- FCKYPQBAHLOOJQ-NXEZZACHSA-N 2-[[(1r,2r)-2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)[C@@H]1CCCC[C@H]1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-NXEZZACHSA-N 0.000 claims 1
- WQMQRNCPZFUGID-UHFFFAOYSA-N 2-azaniumyladamantane-2-carboxylate Chemical compound C1C(C2)CC3CC1C(C(O)=O)(N)C2C3 WQMQRNCPZFUGID-UHFFFAOYSA-N 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- VDCKNAOHKCIAOW-UHFFFAOYSA-N 2-methyl-1-[2-[(2-methyl-2-sulfanylpropyl)amino]ethylamino]propane-2-thiol Chemical compound CC(C)(S)CNCCNCC(C)(C)S VDCKNAOHKCIAOW-UHFFFAOYSA-N 0.000 claims 1
- FHJXLSAWYORMMX-UHFFFAOYSA-N 9-aminobicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound C1CCC2CCCC1C2(N)C(O)=O FHJXLSAWYORMMX-UHFFFAOYSA-N 0.000 claims 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 claims 1
- 101100294331 Drosophila melanogaster nod gene Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000050267 Neurotensin Human genes 0.000 claims 1
- 101800001814 Neurotensin Proteins 0.000 claims 1
- QZYPLCPZHWDJHF-UHFFFAOYSA-N O[PH2]=O.C1CNCCNCCN1 Chemical compound O[PH2]=O.C1CNCCNCCN1 QZYPLCPZHWDJHF-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (50)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16182597.1 | 2016-08-03 | ||
EP16182597.1A EP3279197A1 (en) | 2016-08-03 | 2016-08-03 | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
PCT/EP2017/069570 WO2018024789A1 (en) | 2016-08-03 | 2017-08-02 | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019104888A true RU2019104888A (en) | 2020-09-04 |
RU2019104888A3 RU2019104888A3 (en) | 2020-10-09 |
RU2796538C2 RU2796538C2 (en) | 2023-05-25 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
RU2019104888A3 (en) | 2020-10-09 |
JP7213493B2 (en) | 2023-01-27 |
CA3032350A1 (en) | 2018-02-08 |
EP3494114A1 (en) | 2019-06-12 |
WO2018024789A1 (en) | 2018-02-08 |
CN109790152B (en) | 2022-05-24 |
CN109790152A (en) | 2019-05-21 |
JP2019523294A (en) | 2019-08-22 |
ES2863662T3 (en) | 2021-10-11 |
EP3279197A1 (en) | 2018-02-07 |
ZA201900669B (en) | 2021-06-30 |
AU2017307325A1 (en) | 2019-02-07 |
US11180511B2 (en) | 2021-11-23 |
AU2017307325B2 (en) | 2021-03-04 |
US20200377523A1 (en) | 2020-12-03 |
EP3494114B1 (en) | 2020-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6899864B2 (en) | Morpholino imaging and therapy | |
JP2019523294A5 (en) | ||
JP4538062B2 (en) | Production and use of novel peptide-type drugs for use with bispecific antibodies | |
CA2489469C (en) | Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer | |
CA3145340A1 (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
IL297678A (en) | Humanised anti kallikrein-2 antibody | |
KR20060041205A (en) | Multivalent carriers of bi-specific antibodies | |
HRP20170735T1 (en) | Oxidized avidin with high residency time in the treated tissues | |
JP7213493B2 (en) | Diagnosis, treatment and prevention of neurotensin receptor-related conditions | |
HRP20230604T1 (en) | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer | |
JP2010535166A5 (en) | ||
FR2650672A1 (en) | PROCESS FOR MARKING PROTEINS OR POLYPEPTIDES WITH TECHNETIUM-99M, CONJUGATE OBTAINED, USE AS IMAGING AGENT, KIT FOR RECONSTITUTION OF THESE CONJUGATES | |
Van Schaijk et al. | Pretargeting of carcinoembryonic antigen–expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen× anti-indium–labeled diethylenetriaminepentaacetic acid antibody | |
EP3910340A1 (en) | Composition for targeting medullary thyroid cancer | |
RU2796538C2 (en) | Diagnosis, treatment and prevention of conditions associated with the neurotensin receptor | |
JP2021511068A (en) | Antibodies to Centrin-1, preparation methods, and their use | |
JP2006523706A (en) | Morpholino imaging and treatment with amplification targeting | |
JP2024518287A (en) | Peptide ligand targeting carbonic anhydrase IX, peptide structure containing the same, and use thereof | |
IL305134A (en) | Dual mode radiotracer and therapeutics | |
Theofilas et al. | iPSC-induced neurons with the V337M MAPT mutation are selectively vulnerable to caspase-mediated cleavage of tau and apoptotic cell death | |
Lau et al. | Targeting Carbonic Anhydrase IX in Tumor Imaging and Theranostic Cancer Therapy | |
van Schaijk et al. | Pretargeting with bispecific anti-renal cell cancer χ anti-DTPA (ln) antibody in three RCC models | |
Wang et al. | iPSC-Induced Neurons with the V337M MAPT Mutation are Selectively Vulnerable to Caspase-Mediated Cleavage of Tau and Apoptotic Cell Death |